DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterised by the accumulation of scar ...

The study found through multi-omics integration analysis that rheumatoid arthritis is a causal factor of idiopathic pulmonary ...

Christopher Kennedy didn't think anything was wrong. Soon, doctors were telling him a double lung transplant was his only ...

Kropski JA, Young LR, Cogan JD, et al. Genetic evaluation and testing of patients and families with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;195 (11):1423-1428. doi:10.1164 ...

Panelists discuss how effective management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) relies on early, accurate diagnosis and multidisciplinary collaboration ...

Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely ...

In this podcast, Drs Jeffrey Swigris and Toby Maher discuss the future of idiopathic pulmonary fibrosis. Find out where we're headed regarding diagnostic and treatment innovations on the near horizon.

Jeffrey J. Swigris, DO: Welcome to Medscape InDiscussion on idiopathic pulmonary fibrosis, or IPF. I'm Dr Jeff Swigris. Today we'll be discussing antifibrotic therapy for patients with IPF.

In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...